Valuation
- Market cap
- 92,055,000
- Revenue TTM
- $0
- Net income TTM
- $-61,800,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 796,900
- Avg volume
- 1,704,312
- Day's range
- $1.24 – $1.31
- Shares out
- 72,484,000
- Stochastic %K
- 16%
- Beta
- -0.28
- Analysts
- Strong Sell
- Price target
- $7.00
Company profile
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of i...
Show more
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 980 9099
- Website
- https://biomeafusion.com
- Address
- 1599 Industrial Road, San Carlos, United States
Latest news
No headlines yet.
